New findings suggest that administering recombinant human erythropoietin to patients admitted to a long-term acute care facility significantly reduces their need for allogeneic blood, investigators reported on January 30th at the Society of Critical Care Medicine’s 32nd Critical Care Congress.
Dr. Michael Silver and Dr. Andrea Bazan of the Kindred Hospitals in Chicago, Illinois, randomized 86 long-term acute care patients to receive 12 weekly doses of recombinant human erythropoietin (40,000 units) or placebo administered subcutaneously while in the long-term acute care facility. All subjects received supplemental iron.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!